Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma

Clinical trial NCT02676869 · COMPLETED

Trial details

NCT number: NCT02676869
Sponsor: Immutep Australia Pty. Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Stage IV Melanoma Stage III Melanoma

Start date: 2016-04-01
Primary completion: 2019-08-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.